阿托伐他汀钙联合依折麦布药物对冠心病治疗效果与安全性分析

Efficacy and Safety of Atto Vastatin Calcium Combined with Ezeimebumin in the Treatment of Coronary Heart Disease

目的对在冠心病的临床治疗中阿托伐他汀钙联合依折麦布药物的效果与安全性进行分析,以期为进一步提高冠心病临床疗效提供参考。方法将漯河医学高等专科学校第二附属医院于2017年5月—2018年11月期间接收的120例冠心病患者纳入本次研究观察范围,并采用抽签的方式将其分为对照组(60例)和观察组(60例),对照组单纯采用阿托伐他汀钙治疗,给予观察组患者阿托伐他汀钙联合依折麦布药物治疗,对两种用药方案下患者的临床治疗总有效率、血脂水平改善情况以及用药不良反应的发生情况进行对比观察。结果与对照组相比,观察组临床治疗总有效率明显更高(P<0.05);治疗前两组患者TC、HDL-C、LDL-C及TG等血脂水平均差异无统计学意义(P>0.05),治疗后两组TC、LDL-C及TG均显著下降,HDL-C均显著上升(P<0.05),且与同时期的对照组相比,治疗后观察组的TC、LDL-C及TG均显著较低,HDL-C明显较高(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论将阿托伐他汀钙联合依折麦布药物应用于冠心病的临床治疗中可取得明显较单纯使用阿托伐他汀钙更高的疗效,有效降低患者的血脂水平且不良反应少,值得推广。

Objective To analyze the efficacy and safety of Atto vastatin calcium combined with ezeimebumin in the treatment of coronary heart disease(CHD), in order to provide reference for further improving the clinical efficacy of coronary heart disease (CHD). Methods 120 patients with coronary heart disease received in the hospital from May,2017 to November,2018 were includ ed in the study,and they were divided into control group(60 cases)and observation group(60 cases)by drawing lots. The control group were treated with Atto vastatin calcium alone,and the observation group were treated with Atto vastatin calcium combined with Ezeimebumin. The rate, the improvement of blood lipid level and the occurrence of adverse drug reactions were compared and ob served. Results Compared with the control group,the total effective rate of the observation group was significantly higher than that of the control group(P<0.05). Before treatment,there was no significant difference in blood lipid levels of TC,HDL-C,LDL-C and TG between the two groups(P>0.05). After treatment,the levels of TC,LDL-C and TG decreased significantly,and HDL-C in creased significantly in both groups(P<0.05). Compared with the control group in the same period,the TC,LDL-C and TG were significantly lower and the HDL-C was significantly higher in the observation group after treatment(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The application of Atto vastatin calci um combined with ezeimebumin in the clinical treatment of coronary heart disease is more effective than using Atto vastatin calcium alone. It can effectively reduce the level of blood lipids and has fewer adverse reactions. It is worth popularizing.